secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001818382-25-000030
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte posts Q4 net loss of $20.9M; Symvess commercial launch underway after FDA approval
--------------------------------------------------------------------------------

- Net loss Q4 2024 $20.9M vs $25.1M Q4 2023; full year net loss $148.7M vs $110.8M.
- Cash $95.3M at Dec 31, 2024; raised $46.6M net in March 2025 public offering.
- FDA approved Symvess Dec 19, 2024 for extremity vascular trauma; first commercial shipments to two Level 1 trauma centers in Feb 2025.
- 34 hospitals started VAC approval process; 3 approved; first sales recorded.
- R&D expenses $88.6M in 2024 (up 16% YoY); no revenue in period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838225000030/0001818382-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838225000030/huma-20250328.htm
  HTML page:      https://secwatch.observer/filing/0001818382-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer